Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 74366E102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| BlackRock, Inc. 13G/A | 13.8% |
10/17/2025
Event 9/30/2025
|
||
|
Farallon Capital Management, L.L.C.
13G/A
|
10.0% |
8/13/2026
Event 6/30/2026
|
||
| Farallon Capital Management, L.L.C. | 10.0% | |||
| Farallon Capital Partners, L.P. | 0% | |||
| Farallon Capital Institutional Partners, L.P. | 0% | |||
| Farallon Capital Institutional Partners II, L.P. | 0% | |||
| Farallon Capital Institutional Partners III, L.P. | 0% | |||
| Four Crossings Institutional Partners V, L.P. | 0% | |||
| Farallon Capital Offshore Investors II, L.P. | 0% | |||
| Farallon Capital (AM) Investors, L.P. | 0% | |||
| Farallon Capital F5 Master I, L.P. | 0% | |||
| Farallon Healthcare Partners Master, L.P. | 0% | |||
| Farallon Partners, L.L.C. | 0% | |||
| Farallon Institutional (GP) V, L.L.C. | 0% | |||
| Farallon F5 (GP), L.L.C. | 0% | |||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | |||
| Dapice Joshua J. | 10.0% | |||
| Dreyfuss, Philip D. | 10.0% | |||
| Dunn Hannah E. | 10.0% | |||
| Gehani, Varun N. | 10.0% | |||
| Giauque, Nicolas | 10.0% | |||
| Husen, Avner A. | 10.0% | |||
| Kim, David T. | 10.0% | |||
| Linn, Michael G. | 10.0% | |||
| Luo Patrick (Cheng) | 10.0% | |||
| Roberts, Jr., Thomas G. | 10.0% | |||
| Saito Edric C. | 10.0% | |||
| Short Daniel S. | 10.0% | |||
| Spokes, Andrew J. M. | 10.0% | |||
| Warren, John R. | 10.0% | |||
| Wehrly, Mark C. | 10.0% | |||
|
Farallon Capital Partners, L.P.
13G/A
|
10.0% |
2/6/2026
Event 12/31/2025
|
||
| Farallon Capital Partners, L.P. | 0.5% | |||
| Farallon Capital Institutional Partners, L.P. | 0.5% | |||
| Farallon Capital Institutional Partners II, L.P. | 0.1% | |||
| Farallon Capital Institutional Partners III, L.P. | 0.1% | |||
| Four Crossings Institutional Partners V, L.P. | 0.1% | |||
| Farallon Capital Offshore Investors II, L.P. | 0.9% | |||
| Farallon Capital (AM) Investors, L.P. | 0.1% | |||
| Farallon Capital F5 Master I, L.P. | 0.2% | |||
| Farallon Healthcare Partners Master, L.P. | 7.6% | |||
| Farallon Partners, L.L.C. | 9.8% | |||
| Farallon Institutional (GP) V, L.L.C. | 0.1% | |||
| Farallon F5 (GP), L.L.C. | 0.2% | |||
| Farallon Healthcare Partners (GP), L.L.C. | 7.6% | |||
| Dapice Joshua J. | 10.0% | |||
| Dreyfuss, Philip D. | 10.0% | |||
| Dunn Hannah E. | 10.0% | |||
| Fried, Richard B | 0% | |||
| Gehani, Varun N. | 10.0% | |||
| Giauque, Nicolas | 10.0% | |||
| Husen, Avner A. | 10.0% | |||
| Kim, David T. | 10.0% | |||
| Linn, Michael G. | 10.0% | |||
| Luo Patrick (Cheng) | 10.0% | |||
| Patel, Rajiv A. | 0% | |||
| Roberts, Jr., Thomas G. | 10.0% | |||
| Saito Edric C. | 10.0% | |||
| Seybold, William | 0% | |||
| Short Daniel S. | 10.0% | |||
| Spokes, Andrew J. M. | 10.0% | |||
| Warren, John R. | 10.0% | |||
| Wehrly, Mark C. | 10.0% | |||
|
RTW Investments, LP
13G/A
|
8.1% |
2/17/2026
Event 12/31/2025
|
||
| RTW Investments, LP | 8.1% | |||
| Roderick Wong | 8.1% | |||
| Vanguard Portfolio Management LLC 13G | 5.5% |
4/29/2026
Event 3/31/2026
|
||
| State Street Corp 13G | 5.2% |
8/7/2026
Event 6/30/2026
|
||
|
Wellington Management Group LLP
13G
|
5.1% |
2/10/2026
Event 12/31/2025
|
||
| Wellington Management Group LLP | 5.1% | |||
| Wellington Group Holdings LLP | 5.1% | |||
| Wellington Investment Advisors Holdings LLP | 5.1% | |||
| Vanguard Capital Management LLC 13G | 5.1% |
4/30/2026
Event 3/31/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Biotechnology Value Fund L P
13G/A
|
4.1% |
11/14/2025
Event 9/30/2025
|
||
| Biotechnology Value Fund L P | 2.1% | |||
| BVF I GP LLC | 2.1% | |||
| Biotechnology Value Fund II LP | 1.7% | |||
| BVF II GP LLC | 1.7% | |||
| Biotechnology Value Trading Fund OS LP | 0.2% | |||
| BVF Partners OS Ltd. | 0.2% | |||
| BVF GP Holdings LLC | 3.8% | |||
| BVF Partners L P/IL | 4.1% | |||
| BVF Inc/IL | 4.1% | |||
| Lampert Mark N | 4.1% | |||
|
Deep Track Capital, LP
13G/A
|
2.8% |
11/14/2025
Event 9/30/2025
|
||
| Deep Track Capital, LP | 2.8% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 2.8% | |||
| David Kroin | 2.8% | |||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 10 | 6.19 k | $873 k |
| 2026 Q2 | 361 | 83.0 M | $9.35 B |
| 2026 Q1 | 339 | 78.8 M | $8.31 B |
| 2025 Q4 | 338 | 71.0 M | $6.18 B |
| 2025 Q3 | 286 | 70.9 M | $4.71 B |
| 2025 Q2 | 290 | 71.5 M | $3.95 B |
| 2025 Q1 | 299 | 65.4 M | $3.16 B |
| 2024 Q4 | 255 | 63.8 M | $2.46 B |
| 2024 Q3 | 253 | 62.3 M | $2.80 B |
| 2024 Q2 | 200 | 59.8 M | $2.07 B |
| 2024 Q1 | 196 | 64.0 M | $1.85 B |
| 2023 Q4 | 165 | 59.6 M | $1.37 B |
| 2023 Q3 | 151 | 56.8 M | $947 M |
| 2023 Q2 | 188 | 56.7 M | $1.57 B |
| 2023 Q1 | 161 | 53.2 M | $1.23 B |
| 2022 Q4 | 147 | 52.8 M | $576 M |
| 2022 Q3 | 138 | 47.5 M | $400 M |
| 2022 Q2 | 147 | 53.4 M | $422 M |
| 2022 Q1 | 157 | 50.7 M | $1.20 B |
| 2021 Q4 | 175 | 49.9 M | $1.70 B |
| 2021 Q3 | 150 | 46.4 M | $821 M |
| 2021 Q2 | 143 | 48.2 M | $2.16 B |
| 2021 Q1 | 131 | 44.3 M | $1.15 B |
| 2020 Q4 | 135 | 44.1 M | $889 M |
| 2020 Q3 | 94 | 37.3 M | $728 M |
| 2020 Q2 | 88 | 34.3 M | $605 M |
| 2020 Q1 | 80 | 23.4 M | $165 M |
| 2019 Q4 | 84 | 23.5 M | $165 M |
| 2019 Q3 | 78 | 18.9 M | $228 M |
| 2019 Q2 | 67 | 17.2 M | $208 M |
| 2019 Q1 | 65 | 15.1 M | $189 M |
| 2018 Q4 | 68 | 14.0 M | $94.0 M |
| 2018 Q3 | 64 | 16.2 M | $167 M |
| 2018 Q2 | 70 | 14.2 M | $95.6 M |
| 2018 Q1 | 71 | 11.9 M | $103 M |
| 2017 Q4 | 66 | 11.8 M | $246 M |
| 2017 Q3 | 41 | 8.13 M | $144 M |
| 2017 Q2 | 44 | 8.12 M | $91.8 M |
| 2017 Q1 | 41 | 8.02 M | $103 M |
| 2016 Q4 | 39 | 8.00 M | $175 M |
| 2016 Q3 | 34 | 6.90 M | $145 M |